---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-21-011095"
form_type: "8-K"
ticker: "TENX"
cik: "0000034956"
company_name: "TENAX THERAPEUTICS, INC."
filed_at: "2021-10-14T23:59:59+00:00"
generated_at: "2026-06-28T20:57:19.233591+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tenax Therapeutics President/CFO Michael Jebsen to depart Oct 29; CEO Giordano becomes President; interim CFO appointed

## Summary
- Michael B. Jebsen (President & CFO) to depart Oct 29, 2021; receives 12 months base salary severance + prorated bonus.
- CEO Christopher T. Giordano will assume additional role of President effective upon separation.
- Eliot M. Lurier appointed Interim CFO via Danforth Advisors; Danforth receives $400/hour for his services.
- Jebsen to provide advisory services through April 2022 at $275/hour under a 6-month consulting agreement.
- Board initiates search for a permanent Chief Financial Officer.

## SEC filing metadata
- accession: 0001654954-21-011095
- form_type: 8-K
- ticker: TENX
- cik: 0000034956
- company_name: TENAX THERAPEUTICS, INC.
- filed_at: 2021-10-14T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/34956/000165495421011095/0001654954-21-011095-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/34956/000165495421011095/tenx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-21-011095
- JSON: https://secwatch.observer/filing/0001654954-21-011095.json
- Plain text: https://secwatch.observer/filing/0001654954-21-011095.txt

## Key facts
- Executive change
  Michael B. Jebsen departed as President at TENAX THERAPEUTICS, INC..
  - Action: separated
  - Role: President
  source text: Michael B. Jebsen, the Company's President and Chief Financial Officer, agreed that Mr. Jebsen would separate from the Company effective October 29, 2021
  evidence_url: https://www.sec.gov/Archives/edgar/data/34956/000165495421011095/0001654954-21-011095-index.htm
- Executive change
  Christopher T. Giordano changed role as President at TENAX THERAPEUTICS, INC..
  - Action: assumed additional role of
  - Role: President
  source text: the Company’s current Chief Executive Officer and principal executive officer, Christopher T. Giordano, will assume the additional position of President of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/34956/000165495421011095/0001654954-21-011095-index.htm
- Executive change
  Michael B. Jebsen departed as Chief Financial Officer at TENAX THERAPEUTICS, INC..
  - Action: separated
  - Role: Chief Financial Officer
  source text: Michael B. Jebsen, the Company's President and Chief Financial Officer, agreed that Mr. Jebsen would separate from the Company effective October 29, 2021
  evidence_url: https://www.sec.gov/Archives/edgar/data/34956/000165495421011095/0001654954-21-011095-index.htm
- Executive change
  Eliot M. Lurier was appointed as Interim Chief Financial Officer at TENAX THERAPEUTICS, INC..
  - Action: appointed
  - Role: Interim Chief Financial Officer
  source text: the Company has entered into a consulting agreement with Danforth Advisors, LLC (“Danforth”), dated October 14, 2021, providing for the engagement of Eliot M. Lurier, a consultant with Danforth, as Interim Chief Financial Officer of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/34956/000165495421011095/0001654954-21-011095-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.